Verapamil enhances high-density lipoprotein processing in Hep G2 cells preloaded with cholesterol.
The effects of the calcium channel blocker of the arylalkylamine series verapamil have been investigated on high-density lipoprotein (HDL3) catabolism in the human hepatoma cell line Hep G2. It was found that verapamil markedly enhanced HDL3 binding, uptake and degradation in Hep G2 cells preloaded with nonlipoprotein cholesterol. This effect was dose-dependent, and a 1.5-2-fold increase of the three studied parameters was observed in cells pretreated 24 h with 100 microM verapamil. No significant effect of the drug was found in cells not preincubated with cholesterol. Verapamil induced an increase in the cellular cholesterol content in preloaded cells. Other calcium antagonists such as diltiazem, nifedipine, nitrendipine or amphiphilic drugs such as phenothiazines and propranolol also enhanced HDL3 uptake by Hep G2 cells. These effects of verapamil on HDL3 metabolism could be related to its amphiphilic characteristics, and to its calcium antagonist properties.
Chappey-Gillet
B
B
Laboratoire de Biochimie, Faculté de Médecine Saint-Antoine, Paris, France.
Salmon
S
S
Mazière
C
C
Auclair
M
M
Mazière
J C
JC
D002121:Calcium Channel Blockers / Q000494:pharmacology; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000378:metabolism*; D002784:Cholesterol / Q000378:metabolism*; D006801:Humans; D006868:Hydrolysis; D008075:Lipoproteins, HDL / Q000378:metabolism*; D008113:Liver Neoplasms; D010640:Phenothiazines / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D014700:Verapamil / Q000494:pharmacology*
D002121:Calcium Channel Blockers; D008075:Lipoproteins, HDL; D010640:Phenothiazines; D002784:Cholesterol; D011433:Propranolol; D014700:Verapamil